4//SEC Filing
Kirkpatrick Lynn 4
Accession 0001192482-21-000618
CIK 0001716947other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:11 PM ET
Size
19.7 KB
Accession
0001192482-21-000618
Insider Transaction Report
Form 4
Kirkpatrick Lynn
DirectorChief Executive Officer
Transactions
- Award
Stock Option
2021-06-30+99,950→ 99,950 totalExercise: $3.21Exp: 2022-12-01→ Common Stock (99,950 underlying) - Award
Stock Option
2021-06-30+9,994→ 9,994 totalExercise: $3.21Exp: 2022-12-21→ Common Stock (9,994 underlying) - Award
Stock Option
2021-06-30+460,950→ 460,950 totalExercise: $1.83Exp: 2027-01-04→ Common Stock (460,950 underlying) - Award
Common Stock
2021-06-30+284,851→ 284,851 total - Award
Stock Option
2021-06-30+263,400→ 263,400 totalExercise: $3.19Exp: 2026-01-15→ Common Stock (263,400 underlying) - Award
Stock Option
2021-06-30+817,560→ 817,560 totalExercise: $1.68Exp: 2028-02-05→ Common Stock (817,560 underlying) - Award
Stock Option
2021-06-30+658,500→ 658,500 totalExercise: $2.59Exp: 2029-02-28→ Common Stock (658,500 underlying) - Award
Stock Option
2021-06-30+6,585→ 6,585 totalExercise: $2.59Exp: 2029-03-14→ Common Stock (6,585 underlying)
Footnotes (2)
- [F1]On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock.
- [F2]Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.
Documents
Issuer
Ensysce Biosciences, Inc.
CIK 0001716947
Entity typeother
Related Parties
1- filerCIK 0001418785
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:11 PM ET
- Size
- 19.7 KB